Ansa Biotechnologies Raises $71.5 Million in Series C Funding

Ansa Biotechnologies has raised $71.5 million in an oversubscribed Series C funding round to expand its DNA synthesis technology and support growing demand for high-quality synthetic DNA.

The funding will help the California-based biotechnology company scale its guaranteed DNA synthesis platform and expand its ability to serve customers across the biotechnology and pharmaceutical industries.

Ansa Biotechnologies focuses on developing synthetic DNA solutions that help researchers and companies build complex DNA sequences more efficiently. Its technology is designed to address some of the limitations of traditional DNA synthesis methods, particularly when producing long and complex DNA sequences.

The $71.5 million investment round was led by Blue Water Life Science Advisors and included new investors Illumina Ventures, BEVC, Lightscape Partners and Agent Capital. Existing investors Cerberus Ventures, Fall Line Capital, Dauntless Ventures and Altitude Life Science Ventures also participated. With this latest investment, Ansa’s total funding has reached $211 million since its launch.

The company plans to use the funding to increase manufacturing capacity, expand operations and meet rising customer demand. Over the past year, Ansa has already quadrupled its manufacturing capacity to support its growing business.

Ansa’s enzymatic DNA synthesis platform is designed to produce long and complex DNA sequences that can be difficult to manufacture using conventional methods. The company offers sequence-perfect clonal DNA of up to 50 kilobases, as well as sequence-verified linear double-stranded DNA fragments.

These products have applications in drug discovery, cell and gene therapies, vaccine development and agricultural genomics. The technology could also support AI-driven drug discovery by helping researchers turn computer-designed biological sequences into physical DNA for testing and further development.

As part of the funding announcement, Ansa also welcomed three new members to its board of directors: Nick Naclerio, founding partner of Illumina Ventures; Brad Crutchfield, an experienced life science industry executive; and Nate Cornell, founder and chief investment officer of Blue Water Life Science Advisors.

Ansa CEO Jason T. Gammack said the investment reflects growing customer demand for reliable access to complex DNA sequences. He added that the funding will help the company expand its capabilities, serve more customers and support further innovation in synthetic biology.

The latest financing highlights increasing investor interest in DNA synthesis technologies as advances in artificial intelligence and biotechnology create demand for more complex biological tools.

Comments (0)
Add Comment